[1]
|
Siegel, R.L., Miller, K.D., Fuchs, H.E., et al. (2022) Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians, 72, 7-33. https://doi.org/10.3322/caac.21708
|
[2]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020, GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[3]
|
Zheng, R.S., Zhang, S.W., Zeng, H.M., Wang, S.M., et al. (2016) Cancer Incidence and Mortality in China. Journal of the National Cancer Center, 2, 1-9. https://doi.org/10.1016/j.jncc.2022.02.002
|
[4]
|
周晓军, 余英豪, 等. 肾脏肿瘤[J]. 临床病理诊断与鉴别诊断-泌尿及男性生殖系统疾病, 2020, 8(1): 112-163.
|
[5]
|
Williamson, S.R., Gill, A.J., Argani, P., et al. (2020) Report from the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: III: Molecular Pathology of Kidney Cancer. The American Journal of Surgical Pathology, 44, E47-E65. https://doi.org/10.1097/PAS.0000000000001476
|
[6]
|
宋雪雪, 许周毅, 丁晓琴, 等. 伴有极向反转的乳头状肾肿瘤一例[J]. 中华病理学杂志, 2020(4): 358-360.
|
[7]
|
Michalova, K., Steiner, P., Alaghehbandan, R., et al. (2018) Papillary Renal Cell Carcinoma with Cytologic and Molecular Genetic Features Overlapping with Renal Oncocytoma: Analysis of 10 Cases. Annals of Diagnostic Pathology, 35, 1-6. https://doi.org/10.1016/j.anndiagpath.2018.01.010
|
[8]
|
Kim, S.S., Cho, Y.M., Kim, G.H., et al. (2020) Recurrent KRAS Mutations Identified in Papillary Renal Neoplasm with Reverse Polarity—A Comparative Study with Papillary Renal Cell Carcinoma. Modern Pathology, 33, 690-699. https://doi.org/10.1038/s41379-019-0420-8
|
[9]
|
He, H., Xu, C., Cheng, Z., et al. (2019) Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers. Current Topics in Medicinal Chemistry, 19, 2128-2142. https://doi.org/10.2174/1568026619666190902150555
|
[10]
|
Al-Obaidy, K.I., Eble, J.N., Cheng, L., et al. (2019) Papillary Renal Neoplasm with Reverse Polarity: A Morphologic, Immunohistochemical, and Molecular Study. The American Journal of Surgical Pathology, 43, 1099-1111. https://doi.org/10.1097/PAS.0000000000001288
|
[11]
|
Trpkov, K., Hes, O., Williamson, S.R., et al. (2021) New Developments in Existing WHO Entities and Evolving Molecular Concepts: The Genitourinary Pathology Society (GUPS) Update on Renal Neoplasia. Modern Pathology, 34, 1392-1424. https://doi.org/10.1038/s41379-021-00779-w
|
[12]
|
王彦, 种道臣, 信方杰, 等. 肾脏杂合性嗜酸细胞/嫌色细胞肿瘤的临床病理学特征[J]. 中华病理学杂志, 2021, 50(2): 97-102.
|
[13]
|
Ruiz-Cordero, R., Rao, P., Li, L.R., et al. (2019) Hybrid Oncocytic/Chromophobe Renal Tumors Are Molecularly Distinct from Oncocytoma and Chromophobe Renal Cell Carcinoma. Modern Pathology, 32, 1698-1707. https://doi.org/10.1038/s41379-019-0304-y
|
[14]
|
Idoate, M.A., Trigo, I., Saenz De Zaitigui, J., et al. (2021) Morphological and Molecular Study of Hybrid Oncocytic/Chromophobe Tumor of the Kidney Associated with Sporadic Renal Oncocytosis and Chronic B-Cell Lymphocytic Leukemia: The Possible Contribution of Lymphoma to Renal Oncocytosis. Pathobiology, 88, 313-322. https://doi.org/10.1159/000515215
|
[15]
|
Trpkov, K. and Hes, O. (2019) New and Emerging Renal Entities: A Perspective Post WHO 2016 Classification. Histopathology, 74, 31-59. https://doi.org/10.1111/his.13727
|
[16]
|
Trpkov, K., Williamson, S.R., Gao, Y., et al. (2019) Low-Grade Oncocytic Tumour of Kidney (CD117-Negative, Cytokeratin 7-Positive): A Distinct Entity? Histopathology, 75, 174-184. https://doi.org/10.1111/his.13865
|
[17]
|
Kravtsov, O., Gupta, S., Cheville, J.C., et al. (2021) Low-Grade Oncocytic Tumor of Kidney (CK7-Positive, CD117-Negative): Incidence in a Single Institutional Experience with Clinicopathological and Molecular Characteristics. Human Pathology, 114, 9-18. https://doi.org/10.1016/j.humpath.2021.04.013
|
[18]
|
Webster, B.R., Rompre-Brodeur, A., Daneshvar, M., et al. (2021) Kidney Cancer: From Genes to Therapy. Current Problems in Cancer, 45, Article ID: 100773. https://doi.org/10.1016/j.currproblcancer.2021.100773
|
[19]
|
Linehan, W.M., Schmidt, L.S., Crooks, D.R., et al. (2019) The Metabolic Basis of Kidney Cancer. Cancer Discovery, 9, 1006-1021. https://doi.org/10.1158/2159-8290.CD-18-1354
|
[20]
|
Yang, B., Duan, H.Q., Cao, W.F., et al. (2019) Xp11 Translocation Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma with TFE3 Strong Positive Immunostaining: Morphology, Immunohistochemistry, and FISH Analysis. Modern Pathology, 32, 1521-1535. https://doi.org/10.1038/s41379-019-0283-z
|
[21]
|
Pei, J.M., Cooper, H., Flieder, D.B., et al. (2019) NEAT1-TFE3 and KAT6A-TFE3 Renal Cell Carcinomas, New Members of MiT Family Translocation Renal Cell Carcinoma. Modern Pathology, 32, 710-716. https://doi.org/10.1038/s41379-018-0191-7
|
[22]
|
Caliò, A., Brunelli, M., Segala, D., et al. (2020) Comprehensive Analysis of 34 MiT Family Translocation Renal Cell Carcinomas and Review of the Literature: Investigating Prognostic Markers and Therapy Targets. Pathology, 52, 297-309. https://doi.org/10.1016/j.pathol.2019.11.006
|
[23]
|
Harada, S., Caliò, A., Janowski, K.M., et al. (2021) Diagnostic Utility of One-Stop Fusion Gene Panel to Detect TFE3/TFEB Gene Rearrangement and Amplification in Renal Cell Carcinomas. Modern Pathology, 34, 2055-2063. https://doi.org/10.1038/s41379-021-00858-y
|
[24]
|
Zhan, H.-Q., Qin, R., Li, Y.-L., et al. (2021) TFEB Promotes BCL-2 Expression by Upregulating Its Promoter Activity in the T(6;11) Translocation Renal Cell Carcinomas. American Journal of Translational Research, 13, 8804-8818.
|
[25]
|
Zyla, R.E. and Hodgson, A. (2021) Gene of the Month: FH. Journal of Clinical Pathology, 74, 615-619. https://doi.org/10.1136/jclinpath-2021-207830
|
[26]
|
Crooks, D.R., Maio, N., Lang, M., et al. (2021) Mitochondrial DNA Alterations Underlie an Irreversible Shift to Aerobic Glycolysis in Fumarate Hydratase-Deficient Renal Cancer. Science Signaling, 14, eabc4436. https://doi.org/10.1126/scisignal.abc4436
|
[27]
|
Lau, H.D., Chan, E., Fan, A.C., et al. (2020) A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-Deficient Renal Cell Carcinoma in 32 Patients. The American Journal of Surgical Pathology, 44, 98-110. https://doi.org/10.1097/PAS.0000000000001372
|
[28]
|
Gleeson, J.P., Nikolovski, I., Dinatale, R., et al. (2021) Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. Clinical Cancer Research, 27, 2910-2919. https://doi.org/10.1158/1078-0432.CCR-20-4367
|
[29]
|
Szymanski, M., Rusetska, N., Jancewicz, I., et al. (2021) Succinate Dehydrogenase-Deficient Renal Cancer Featuring Fructose-1, 6-Biphosphatase Loss, Pyruvate Kinase M2 Overexpression, and SWI/SNF Chromatin Remodeling Complex Aberrations: A Rare Case Report. Oncologist, 26, E1652-E1655. https://doi.org/10.1002/onco.13825
|
[30]
|
Sturrock, B.R.H., Macnamara, E.F., McGuire, P., et al. (2021) Progressive Cerebellar Atrophy in a Patient with Complex II and III Deficiency and a Novel Deleterious Variant in SDHA: A Counseling Conundrum. Molecular Genetics & Genomic Medicine, 9, E1692. https://doi.org/10.1002/mgg3.1692
|
[31]
|
Tsai, T.-H. and Lee, W.-Y. (2019) Succinate Dehydrogenase-Deficient Renal Cell Carcinoma. Archives of Pathology & Laboratory Medicine, 143, 643-647. https://doi.org/10.5858/arpa.2018-0024-RS
|
[32]
|
Trpkov, K. and Siadat, F. (2019) Immunohistochemical Screening for the Diagnosis of Succinate Dehydrogenase-Deficient Renal Cell Carcinoma and Fumarate Hydratase-Deficient Renal Cell Carcinoma. Annals of Translational Medicine, 7, S324. https://doi.org/10.21037/atm.2019.09.143
|
[33]
|
Varchetta, V., Campanella, C., Rossi, M., et al. (2021) Identification of Anaplastic Lymphoma Kinase Fusion in Clear Cell Renal Carcinoma (ALK-TRCC): A Precision Oncology Medicine Case Report. Recenti Progressi in Medicina, 112, 14e-15e.
|
[34]
|
Siadat, F. and Trpkov, K. (2020) ESC, ALK, HOT and LOT: Three Letter Acronyms of Emerging Renal Entities Knocking on the Door of the WHO Classification. Cancers (Basel), 12, Article No. 168. https://doi.org/10.3390/cancers12010168
|
[35]
|
Kuroda, N., Trpkov, K., Gao, Y., et al. (2020) ALK Rearranged Renal Cell Carcinoma (ALK-RCC): A Multi-Institutional Study of Twelve Cases with Identification of Novel Partner Genes CLIP1, KIF5B and KIAA1217. Modern Pathology, 33, 2564-2579. https://doi.org/10.1038/s41379-020-0578-0
|
[36]
|
周露婷, 杨晓群, 许建昆, 等. 嗜酸性实性囊性肾细胞癌7例临床及分子病理特征分析[J]. 临床与实验病理学杂志, 2020, 36(12): 1407-1411.
|
[37]
|
Hes, O. and Trpkov, K. (2022) Do We Need an Updated Classification of Oncocytic Renal Tumors? Emergence of Low-Grade Oncocytic Tumor (LOT) and Eosinophilic Vacuolated Tumor (EVT) as Novel Renal Entities. Modern Pathology, 35, 1140-1150. https://doi.org/10.1038/s41379-022-01057-z
|
[38]
|
Kapur, P., Gao, M., Zhong, H., et al. (2021) Eosinophilic Vacuolated Tumor of the Kidney: A Review of Evolving Concepts in This Novel Subtype with Additional Insights from a Case with MTOR Mutation and Concomitant Chromosome 1 Loss. Advances in Anatomic Pathology, 28, 251-257. https://doi.org/10.1097/PAP.0000000000000299
|
[39]
|
Farcaş, M., Gatalica, Z., Trpkov, K., et al. (2022) Eosinophilic Vacuolated Tumor (EVT) of Kidney Demonstrates Sporadic TSC/MTOR Mutations: Next-Generation Sequencing Multi-Institutional Study of 19 Cases. Modern Pathology, 35, 344-351. https://doi.org/10.1038/s41379-021-00967-8
|